<DOC>
	<DOCNO>NCT01128894</DOCNO>
	<brief_summary>This open-label study examines efficacy safety albiglutide compare liraglutide subject type 2 diabetes .</brief_summary>
	<brief_title>A Study Determine Efficacy Safety Albiglutide Compared With Liraglutide .</brief_title>
	<detailed_description>This randomize , open-label , multicenter , 2 parallel-group study evaluate efficacy safety weekly subcutaneously inject dose albiglutide compare liraglutide . Subjects historical diagnosis type 2 diabetes mellitus whose glycemia inadequately control current regimen metformin , thiazolidinedione , sulfonylurea , combination oral antidiabetic recruit study .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>rGLP-1 protein</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Diagnosis type 2 diabetes mellitus experience inadequate glycemic control current regimen metformin , TZD , SU , combination oral antidiabetic medication BMI &gt; /=20kg/m2 &lt; /=45 kg/m2 Fasting Cpeptide &gt; /=0.8 ng/mL ( &gt; /=0.26 nmol/L ) HbA1c 7.0 % 10.0 % , inclusive Female subject childbearing potential must practice adequate contraception . History cancer History treat diabetic gastroparesis Current biliary disease history pancreatitis History significant GI surgery Recent clinically significant cardiovascular and/or cerebrovascular disease Hypertension History human immunodeficiency virus infection History current liver disease acute symptomatic infection hepatitis B hepatitis C History alcohol substance abuse Female subject pregnant , lactating , &lt; 6 week postpartum Known allergy GLP 1 analogue , liraglutide , study medication ' excipients , excipients albiglutide , Baker 's yeast History type 1 diabetes mellitus Contraindications ( per prescribe information ) use either background potential randomize study medication ( e.g. , liraglutide ) Receipt investigational drug liraglutide within 30 day 5 half life , whichever longer , Screening history receipt investigational antidiabetic drug within 3 month randomization receipt albiglutide previous study History family history thyroid disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>GSK716155</keyword>
	<keyword>liraglutide</keyword>
	<keyword>albiglutide</keyword>
	<keyword>open-label</keyword>
</DOC>